Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of DTaPgen in Healthy Toddlers
NCT07213089Phase 3Completed
- Sponsor
- BioNet
- Start
- Jul 2020
- Primary completion
- Apr 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of DTaPgen in pertussis, diphtheria and Tetanus (2 arms), sponsored by BioNet. Primary endpoint: Seroconversion rates of PT at 28 days. Started Jul 2020; status: completed.
02
Drugs
DTaPgen
03
Conditions
pertussisdiphtheriaTetanus
Beyond the preview
Go deeper on NCT07213089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07213089.